Due to high call volume during this time, we highly encourage your to utilize our online tool to check your 2020 enrollment status. Click HERE to check your status.  

If you forgot to re-enroll, you may simply use our online application to apply for the current year by clicking HERE

 
Diseases Covered

Myeloproliferative Diseases

Includes: Hypereosinophilic Syndrome, Myelofibrosis, Essential Thrombocytosis, Polycythemia vera
All pictures shown are used for illustrative purposes only.

Program Status

open

Apply Now

We encourage you to apply for assistance; see the qualifications below.
 

Assistance Amount

$ 6,500

Ask your Good Days Patient Care Navigator for more information.

Eligibility Criteria

  • Patient must be diagnosed with a covered disease and program must be accepting enrollments
  • Patient must have a valid Social Security number to apply for assistance and receive treatment in the United States
  • Patient must be seeking assistance for a prescribed medication that is FDA approved to treat the covered diagnosis
  • Patient is required to have valid Medicare or Military insurance coverage
  • Patient income level must be at or below 500% of the Federal Poverty Level (FPL)

Apply Now

  • Agrylin
  • Anagrelide
  • Droxia/Hydrea
  • Gleevec
  • Hydrea
  • Hydroxyurea
  • Imatinib Mesylate
  • Inrebic
  • Jakafi

Chronic myeloproliferative neoplasms are diseases in which the bone marrow makes too many red blood cells, platelets, or certain white blood cells. (Source: NIH; National Cancer Institute)

Medications Covered

  • Agrylin
  • Anagrelide
  • Droxia/Hydrea
  • Gleevec
  • Hydrea
  • Hydroxyurea
  • Imatinib Mesylate
  • Inrebic
  • Jakafi

Disease Description

Chronic myeloproliferative neoplasms are diseases in which the bone marrow makes too many red blood cells, platelets, or certain white blood cells. (Source: NIH; National Cancer Institute)

Apply For Assistance

Speeding your treatment is important to us.

Get Our Newsletter

You're not alone. The Good Days newsletter keeps you up-to-date.